From GlobeNewswire: 2025-06-02 09:45:00

The global hemoglobinopathies market is projected to reach USD 25.68 billion by 2032, with a CAGR of 11.56%. Sickle cell disease and thalassemia are key concerns in regions with limited healthcare infrastructure. The U.S. market is expected to grow to USD 6.66 billion by 2032, driven by genetic testing and innovative therapies like Casgevy and Lyfgenia.

Sickle Cell Disease dominated the market in 2023 with a 57.40% share. Diagnostic advancements like DNA-based methods and HPLC have enabled early detection. Other Hemoglobin (Hb) Variants Therapy accounted for 63.25% of the market, with treatments like blood transfusions and bone marrow transplants driving growth. National programs in China and India are increasing awareness and treatment availability.

North America led the global market in 2023, with the U.S. at the forefront of curative therapies and FDA approvals. Europe has harmonized screening programs, while the Asia-Pacific is enhancing control programs. Recent developments include India’s national registry for screening and partnerships for access to therapies in Sub-Saharan Africa.



Read more at GlobeNewswire: Hemoglobinopathies Market to Reach USD 25.68 Billion by